ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

venetoclax

Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.

Drug pageVenetoclax: every studyAll 486 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 22, 202167 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only5312 open or runningphase 4since Nov 22, 2021Apr 1, 2011Nov 2026phase 2 · NCT04895436
Hoffmann-La Roche131 open or runningphase 3since Dec 4, 2013Aug 10, 2012none ahead
Oncotherapeuticsits history only11 open or runningphase 2since Aug 11, 2023Aug 11, 2023none ahead

Also a collaborator on its studies: Johnson & Johnson, Baili-Bio (Chengdu) Pharmaceutical, Roche-Genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 10, 2012First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT01671904 · 84 enrolled · United States, France, Germany
  2. Sep 12, 2012Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01685892 · 82 enrolled · United States, United Kingdom
  3. Dec 4, 2013Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02005471 · 389 enrolled · United States, Australia, Austria and more
  4. Feb 4, 2014Phase 2 study in Lymphoma, Non-HodgkinNCT02055820 · 267 enrolled · United States, Australia, Austria and more
  5. Jul 9, 2014Phase 2 study in Lymphoma, FollicularNCT02187861 · 163 enrolled · United States, Australia, Belgium and more
  6. Sep 16, 2014Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02242942 · 445 enrolled · United States, Argentina, Australia and more
  7. Oct 12, 2017Phase 2 study in Multiple MyelomaNCT03312530 · 49 enrolled · Czechia, Denmark, France and more
  8. Jun 25, 2018Phase 2 study in Breast NeoplasmsNCT03584009 · 103 enrolled · United States, Australia, Canada and more
  9. Feb 25, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04285567 · 166 enrolled · United States, Australia, France and more
  10. Mar 5, 2020Phase 2 study in Breast NeoplasmsNCT04298918 · 1 enrolled · Australia, Korea, Republic of
  11. Jun 5, 2020Phase 1 study in Small Cell Lung CarcinomaNCT04422210 · 2 enrolled · United States, Denmark, Korea, Republic of and more
  12. Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04790903 · 50 enrolled · United States, France, Italy and more
  13. Jul 23, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06524375 · 118 enrolled · United States

TargetBeta

BCL2 →read by rule
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

All 13 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06524375Leukemia, Lymphocytic, Chronic, B-Cell · United States2Active, not recruitingOct 28, 2026118
NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more1TerminatedMay 21, 202450
NCT04422210Small Cell Lung Carcinoma · United States, Denmark, Korea, Republic of and more1TerminatedNov 6, 20202
NCT04298918Breast Neoplasms · Australia, Korea, Republic of2TerminatedFeb 4, 20211
NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3CompletedMar 19, 2024166
NCT03584009Breast Neoplasms · United States, Australia, Canada and more2TerminatedAug 5, 2020103
NCT03312530Multiple Myeloma · Czechia, Denmark, France and more2CompletedMay 18, 202149
NCT02242942Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedAug 17, 2018445
NCT02187861Lymphoma, Follicular · United States, Australia, Belgium and more2CompletedSep 27, 2016163
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedJun 28, 2017267
NCT02005471Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedMay 8, 2017389
NCT01685892Leukemia, Lymphocytic, Chronic, B-Cell · United States, United Kingdom1CompletedMay 21, 201882
NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany1CompletedAug 17, 201884

How it is read

Names in the registry

  • “Venetoclax”, 66 entries
  • “ABT-199”, 9 entries
  • “venetoclax”, 6 entries
  • “ABT-199 (Main Cohort)”, 1 entry
  • “ABT-199 (Safety Expansion Cohort)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.